An investigational viral immunotherapy extended survival compared with standard care for patients with advanced non-small cell lung cancer who had inadequate response to immune checkpoint inhibitor ...

Afatinib has broad activity against EGFR mutations. However, the approval for uncommon mutations was based on data from 38 ...

Susan Riffle had a lesion on her lung that AI determined was likely cancer. The disease was caught at stage 1, and she avoided chemotherapy and radiation Wendy Grossman Kantor is an award-winning ...

Experimental Cancer Drug Could Streamline Standard Tuberculosis Treatment and Prevent Post-TB Lung Disease, Study Suggests Apr. 21, 2025 — An experimental drug now in clinical trials as a cancer ...

Background: Tobacco is considered the most important cause of lung cancer, but other factors could also be involved in its pathogenesis. The aim of the present work was to establish an association ...

In a study led by a multinational team of experts, researchers at National Jewish Health and their collaborators in Colorado, ...

Lung cancer arises in tissues of the lung, usually in the cells lining air passages. The two main types are small-cell lung cancer and non-small-cell lung cancer, according to the shape of cells ...

Despite new paradigm-shifting treatments, lung cancer remains a deadly disease – and improving outcomes requires more than just drug research. The new Lung Ambition Alliance – launched in July ...

AstraZeneca’s hopes of positioning its PD-L1 inhibitor Imfinzi as a post-surgery therapy for people with earlier-stage lung cancer have taken ... to extend the label of Imfinzi beyond that ...

The American Lung Association in Pennsylvania is turning the Greater Philadelphia area turquoise for Lung Cancer Action Week starting today May 5-11, 2025, to raise awareness about lung cancer, honor ...

There is interest in using quercetin for a number of other purposes, but there isn't enough reliable information to say whether it might be helpful. Pregnancy and breast-feeding: There isn't ...